Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study.
Rebecca A DentJavier CortésLajos PusztaiHeather McArthurSherko KümmelJonas BerghCarsten DenkertYeon Hee ParkRina HuiNadia HarbeckMasato TakahashiMichael UntchPeter A FaschingFatima CardosoAmin HaideraliLiyi JiaAllison Martin NguyenWilbur PanJoyce O'ShaughnessyPeter SchmidPublished in: Journal of the National Cancer Institute (2024)
ClinicalTrials.gov, NCT03036488.